

		n	%
Age (year)	Mean : 60.98 (Range : 23.44-90.07 years)		
Sexe	Men	161	66.8
	Women	80	33.2
RCC Sub-type	Clear	212	88
	Papillary type 1	8	3.3
	Papillary type 2	15	6.2
	Chromophobe	6	2.5
pTNM stage	pT1a	60	24.9
	pT1b	84	34.9
	pT2	22	9.1
	pT3a	26	10.8
	pT3b	49	20.3
Fuhrman grade	1	17	7
	2	92	38.2
	3	95	39.4
	4	37	15.4
Microangioinvasion	Present	70	29
	Absent	171	71
Tumor size (cm)	Mean : 5.8 (Range : 1-19)		
Death	Yes	141	58.5
	No	100	41.5
Death origin	Cancer-related	19	13.5
	Not related to cancer	62	44
	No information	60	42.6

Supplemental Table 1. Clinicopathologic characteristics of the patients.

Group	Sodium mM	Phosphate mM	Chlore mM	Creatinine μM	Albumin g/l	Urea mM	Weight g (Day 0)	Weight g (Day 35/28)
786-0 Ctl	141.1 ±4.3	1.6 ±0.1	107.9 ±2.8	10.8 ±0.4	24.6 ±1.1	8.5 ±0.6	32.8 ±1.0	34.1 ±1.3
786-0 BAY	144.0 ±3.7	2.2 ±0.2	111.9 ±2.9	9.5 ±0.6	24.1 ±0.8	8.1 ±0.4	31.9 ±0.3	30.9 ±0.7
Caki-1 Ctl	122.0 ±1.9	1.5 ±0.1	92.1 ±1.0	8.1 ±0.4	20.9 ±0.3	6.6 ±0.3	31.9 ±0.9	32.7 ±0.7
Caki-1 BAY	129.2 ±6.6	1.8 ±0.3	98.3 ±6.2	8.2 ±0.3	21.7 ±1.1	7.0 ±0.8	31.8 ±0.3	31.4 ±0.5

Supplemental Table 2. Treatments of nude mice with BAY 11-7085 do not affect plasma parameters and body weight. Mice treated for 35 (786-0 tumors-bearing mice) or 28 (Caki-1 tumors-bearing mice) days in control (Ctl) or with BAY 11-7085 were anesthetized and the blood was collected. Concentrations of sodium, phosphate, chlore, creatinine, albumin and urea in plasma were measured. Animal weights were measured at the beginning (Day 0) and at the end (Day 35 or Day 28 for 786-0 or Caki-1 tumors-bearing mice, respectively) of each treatment.

